Some people with Bipolar Disorder have problems with memory, concentration, and decision making skills even when they do not have current symptoms of mania or depression. Such cognitive deficits are associated with impairments in everyday functioning and quality of life. This study is looking at changes in cognitive function in bipolar patients who are treated with 20 to 80mg/day of Lurasidone vs Placebo add on therapy over a 6 week period.

At screen visit neurocognitive testing (paper and pencil tests of memory, problem solving etc) is completed. Participants with cognitive impairment complete clinical assessments, physical examination and laboratory tests. At baseline visit, eligible participant are randomized to receive either Lurasidone or Placebo over 6 weeks. Neurocognitive testing, blood sample collection and clinical assessments are completed at all clinic visits.